Press
BRC-002 receives Orphan Drug Designation from FDA for Complex Regional Pain Syndrome
BRC announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS) to BRC-002, which is being investigated in an investigator-initiated clinical Phase 1 trial.
Read more →
Cannabinoid Product Holds Promise for Patients in Pain
Scientists at City of Hope are testing a pharmaceutical-grade cannabis-based medicine to determine whether it is effective in treating joint pain in breast cancer patients taking aromatase inhibitors
Biopharmaceutical Research Company Announces First Dose of BRC-002, a First-in-Class Cannabinoid Therapeutic for Complex Regional Pain Syndrome (CRPS), in Investigator-Initiated Study
Biopharmaceutical Research Company Announces First Dose of BRC-002, a First-in-Class Cannabinoid Therapeutic for Complex Regional Pain Syndrome (CRPS), in Investigator-Initiated Study Read more →
First patient received BRC-001, a cannabinoid therapeutic, in a clinical trial investigating supportive care in breast cancer at City of Hope.
City of Hope and Biopharmaceutical Research Company announce first patient has received BRC-001 first-in-class cannabinoid therapeutic, in a clinical trial investigating supportive care in breast cancer Read more →
BRC Featured in Stanford Business Magazine for its Novel Approach to Cannabinoid Drugs
The cannabis industry is evolving, moving from a previously illicit market to a more mainstream status, though it still operates within a regulatory and financial gray area. Companies like the Biopharmaceutical Research Company (BRC) and Cresco Labs are leading this change by navigating federal restrictions and scaling up operations. Despite challenges such as state-specific regulations and banking constraints, the industry anticipates substantial growth, driven by increasing legalization and consumer acceptance. Innovations in cannabis products and formulations are also propelling the market forward.
Coffee Talk Podcast: Exploring Cannabis' Role in Longevity with Hunter Land, PhD
Dive into the potential of cannabis in enhancing health span and lifespan with Hunter Land, PhD. Discover the "entourage effect", compare cannabis compounds with other longevity drugs, and explore their potential in preventing disease progression. A must-listen for those interested in cannabis research and longevity studies. Listen to the episode →
Cannabinoid Researcher Urges Industry to Adopt Scientific Mindset
Hunter Land, Vice President of Research and Development at US-based Biopharmaceutical Research Company, has called for the cannabis industry to explore the therapeutic possibilities of the cannabis plant and adopt a more scientific approach to developing medicines. Land urged the industry to move beyond the focus on THC and CBD, stating that there are 148 other cannabinoids that need to be explored. He also criticised the use of the term "strain" and described full spectrum and broad spectrum as ambiguous phrases that create an impression of administering "mystery soup" to patients. Land emphasised the need for the industry to be more specific about the ingredients in cannabis medication and the indications it is targeting. Read more →
DEA-Licensed Cannabis Company Raises $20 Million
Monterey, CA – Biopharmaceutical Research Company (“BRC”), an active Drug Enforcement Administration (DEA) pharmaceutical cannabis license holder, announced the completion of a $20M Series A fundraise. This will enable the Company to aggressively scale its operations and increase its product offering, conduct sponsored research, and execute on its go-to-market strategy. Read more →
Open Book Extracts and BRC establish research and development collaboration
Roxboro, N.C. – Open Book Extracts (OBX), an NSF-certified manufacturer and distributor of the industry's most innovative and highest quality cannabinoid ingredients and finished products, today announces a collaboration with Biopharmaceutical Research Company (BRC). Read more →
BRC completes 1st import of commercial cannabis flower into the USA
The Colombian multinational shipped 30 kilograms of dried cannabis flower from its facilities in Portugal. The company continues to conquer the world in the midst of the 'boom' that the industry is going through. Read more →
BRC partners with Vanguard Scientific on technology integration for cannabis extraction
Biopharmaceutical Research Company partners with Vanguard Scientific on technology integration for cannabis extraction. Read more →
Clever Leaves exports its first commercial shipment of THC flower to the United States to BRC
Clever Leaves Holdings Inc. , a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, announced today the exportation of 30 kg of high-THC cannabis flower from its Portugal facility to Biopharmaceutical Research Company (“BRC”), a DEA-licensed pharmaceutical company that develops federally compliant active pharmaceutical ingredients (API) for plant-based therapeutics in the United States. Read more →
BRC and Segra complete 1st shipment of live cannabis plants into the USA
Segra International Corp, a leading cannabis agriculture technology company, is pleased to announce its first successful export of Verified Segra Stock™ Cannabis plantlets to the Biopharmaceutical Research Company (BRC), one of the first groups in the USA to receive approval from the DEA to cultivate Cannabis for scientific research purposes. Read more →
DEA finally ends fed monopoly on schwaggy research-grade cannabis
Late last week, the U.S. Drug Enforcement Administration (DEA) quietly made an announcement that’s expected to have a profound and long-lasting impact on cannabis research and development in the United States. Read more →
DEA close to allowing companies to grow cannabis for scientific research
After years of delay under the Trump administration, the federal government is preparing to award the first new licenses for cultivating cannabis for scientific research, giving U.S. marijuana operators a crack at entering a business that has been dominated by the University of Mississippi for more than 50 years. Read more →
DEA finally issues permits to grow research-grade pot
The DEA is finalizing the effort to increase the number of permitted research-grade marijuana growers after initially receiving guidance from its own administrative law judge in February 2007. Read more →
US growing approvals a ‘monumental’ step away from Trump moratorium on pot licensing
Last week the US government announced it would begin granting growing approvals to several companies for medicinal marijuana research, ending an informal moratorium on licence issuing which has been in place since the Trump administration. According to a press release from the founder and CEO of Biopharmaceutical Research, George Hodgin, the marijuana manufacturing approvals represent a “monumental step” forward for the American cannabis industry. Read more →
DEA finally ready to end federal marijuana research monopoly
The Drug Enforcement Administration (DEA) on Friday notified several companies that it is moving toward approving their applications to become federally authorized marijuana manufacturers for research purposes. Read more →
Marijuana medical research growers receive U.S. approval
The U.S. government has approved new growers of research marijuana for the first time in more than 50 years, people involved in the process said, widening the capacity to study the drug’s medical value. Read more →
U.N. removing cannabis from schedule IV
Pharmaceutical cannabis: Achieving a consistent product from a highly variable plant “Growing like a weed.” You’ve no doubt heard this phrase before, in reference to the undesirable, relentless pest plants that overtake our gardens. Perhaps not surprisingly, this phrase is also commonly applied to the cannabis plant. Read more →